

## ***Sentinel Lymph Node Biopsy for Melanoma in B.C. (pg. 3)***

1. Canadian Cancer Society. Melanoma: deadliest type of skin cancer is on the rise. 2014;(May):28-31. <http://www.cancer.ca/en/about-us/for-media/media-releases/national/2014/2014-canadian-cancer-statistics/?region=on>
2. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. Published online 2014:599-609. doi:10.1056/NEJMoa1310460
3. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wri ER. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. *New England Journal of Medicine*. 2017;376(23):2211-2222. doi:10.1016/j.physbeh.2017.03.040
4. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncology*. 2016;17(6):757-767. doi:10.1016/S1470-2045(16)00141-8
5. Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. *Journal of Clinical Oncology*. 2018;36(35):3441-3449. doi:10.1200/JCO.18.01219
6. Weber J, Mandala M, del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *New England Journal of Medicine*. 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030
7. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *The New England journal of medicine*. 2018;378(19):1789-1801. doi:10.1056/NEJMoa1802357
8. Lane K, Kempf A, Magno C, et al. Regional Differences in the Use of Sentinel Lymph Node Biopsy for Melanoma: A Potential Quality Measure. *The American Surgeon*. 2008;74(10):981-984.
9. Ollek S, Minkova S, Taqi, K, et al. Population based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma. *Canadian Journal of Surgery*. Manuscript accepted for publication. 2021.

## ***Oncologic Liver Transplant (pg. 7)***

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. *New England Journal of Medicine*. 1996 Mar 14;334(11).

2. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. *Liver Transplantation*. 2011 Oct;17(S2).
3. Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status. *Liver Transplantation*. 2010 Mar;16(3).
4. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma. *Annals of Surgery*. 2005 Sep;242(3).
5. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. *Hepatology*. 2016 Oct;64(4).
6. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. *The Lancet Gastroenterology & Hepatology*. 2018 May;3(5).
7. Rossi RE, Burroughs AK, Caplin ME. Liver Transplantation for Unresectable Neuroendocrine Tumor Liver Metastases. *Annals of Surgical Oncology*. 2014 Jul 22;21(7).
8. Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. *American Journal of Transplantation*. 2016 Oct;16(10).
9. Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. *Surgery*. 2017 Sep;162(3).
10. Dueland S, Yaqub S, Syversveen T, Carling U, Hagness M, Brudvik KW, et al. Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases. *JAMA Surgery*. 2021 Jun 1;156(6).
11. Hagness M, Foss A, Line P-D, Scholz T, Jørgensen PF, Fosby B, et al. Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer. *Annals of Surgery*. 2013 May;257(5).
12. Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, et al. Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. *British Journal of Surgery*. 2018 Feb 5;105(3).

### ***Endoscopy Update: Sessile Serrated Lesions – New name, Same Challenges (pg. 8)***

1. Pai RK, Makinen MJ, Rosty C. Colorectal serrated lesions and polyps. In: Board TWCoTE, ed. *The WHO Classification of Tumours: Digestive System Tumours*. 5th ed. Lyon (France): World Health Organization; 2019:163 to 9.
2. Tadepalli US, et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video) *Gastrointest Endosc*. 2011;74(6):1360–8.
3. Leddin D, Enns R, Hilsden R, et al. Colorectal cancer surveillance after index colonoscopy: guidance from the Canadian Association of Gastroenterology. *Can J Gastroenterol* 2013;27:224-8.